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ABSTRACT
The P2X7 receptor is a ligand-gated cation selective channel which mediates ATP-induced
apoptosis of cells of the immune system.  We and others have shown that P2X7 is non-
functional both in lymphocytes and monocytes from some subjects.  To study a possible
genetic basis we sequenced DNA coding for the carboxyl terminal tail of P2X7.  In 9 of 45
normal subjects a heterozygous nucleotide substitution (A1513C) was found while 1
subject carried the homozygous substitution which codes for glutamic acid to alanine at
amino acid position 496.  Surface expression of P2X7 on lymphocytes was not affected by
this Glu496Ala polymorphism demonstrated both by confocal microscopy and
immunofluorescent staining.  Monocytes and lymphocytes from the Glu496Ala
homozygote subject expressed non-functional receptor while heterozygotes showed P2X7
function which was half that of germline P2X7.  Results of transfection experiments
showed the mutant P2X7 receptor was non-functional when expressed at low receptor
density but regained function at a high receptor density.  This density-dependence of
mutant P2X7 function was also seen on differentiation of fresh monocytes to macrophages
with interferon-γ which upregulated mutant P2X7 and partially restored its function. P2X7-
mediated apoptosis of lymphocytes was impaired in homozygous mutant P2X7 compared
with germline (8.6% versus 35.2%). The data suggest that the glutamic acid at position 496
is required for optimal assembly of the P2X7 receptor.
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INTRODUCTION
Purinergic P2X7 receptors are ligand-gated cation channels, present on cells of the immune
and haemopoietic system, which have been shown to mediate the ATP-induced apoptotic
death of monocytes (1) macrophages (2) and lymphocytes (3,4).  The P2X7 receptor family
have two transmembrane domains with intracellular amino and carboxyl termini and an
oligomeric structure in the plasma membrane based on trimeric or larger complexes of
identical subunits (5). Moreover the P2X7 receptor does not appear to form
heteropolymers with other P2X subtypes(6). The genes for both the rat and human P2X7
receptors have now been cloned and show extensive homology (30 – 40%) with the other
members of the P2X receptor family, although P2X7 differs in having a long carboxyl
terminus of 240 amino acids from the inner membrane face (7). The genomic structure of
P2X7  consists of 13 exons with exon 12 and exon 13 coding for the carboxyl terminal tail
of this molecule.  There is strong evidence that this long carboxyl terminus is necessary for
the permeability properties of the P2X7 receptor since truncation of this tail abolishes ATP
induced uptake of the fluorescent dye YoPro-1 (8).  Studies of P2X7 of monocyte-
macrophages or of lymphocytes as well as HEK-293 cells expressing the cDNA  for P2X7
have shown features which are most unusual for a channel.  These include the slow further
dilatation following channel opening (9)  and the activation of various proteases including
membrane metalloproteases (10) and intracellular caspases (2,11).  The fully dilated state
of the P2X7 pore accepts ethidium cation (314 Da) as a permeant and since ethidium
fluorescence is enhanced on binding to nucleic acids the technique of flow cytometry
allows a sensitive measurement of the initial rate of permeant uptake which is essentially
unidirectional(9). In normal leucocytes a close correlation has been found between ATP
induced ethidium uptake and the surface expression of P2X7 receptors measured by the
binding of a FITC-conjugated antibody to the extracellular domain of this receptor(12).
There is increasing evidence that a genetic factor plays a role in the functional phenotype
of the P2X7 receptor. Thus, Lammas and colleagues (13) have shown that ATP-induced
uptake of the dye lucifer yellow into monocytes was minimal in 2 out of 19  normal donors
while our group has shown a lack of P2X7 function in both lymphocytes and monocytes in
3 out of 12 patients with B-cell chronic lymphocytic leukaemia (CLL) despite strong
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expression of the P2X7 protein (12).  These results led us to search for non-functional P2X7
receptors in a large cohort of normal subjects and study its possible genetic basis.   The
results show a single nucleotide polymorphism is present at low frequency in the
Caucasian population and codes for a glutamic acid to alanine substitution at amino acid
496.  Homozygosity for the polymorphism produces non-functional P2X7 protein while the
heterozygous state gives cells with half the function of cells with germline P2X7 protein.
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MATERIALS AND METHODS
Materials
ATP, BzATP (2’,3’-O-(4-benzoyl)benzoyl ATP), ethidium bromide, barium chloride,
digitonin, D-glucose, BSA (bovine serum albumin), RPMI1640 medium, poly-L-lysine,
gentamicin, 7-AAD (7-amino-actinomycin D) and FluoroTag FITC Conjugation Kit were
purchased from Sigma Chemical Co (St Louis, MO). Ficoll-Hypaque (density 1.077) and
GFXTM PCR DNA and Gel Band Purification Kit was obtained from Amersham
Pharmacia (Uppsala, Sweden). FITC (fluorescein isothiocyanate) and RPE (R-
phycoerythrin) conjugated negative control antibodies, mouse anti-human CD3, CD14,
CD16, CD19 antibodies, and RPE-Cy5 (R-phycoerythrin-Cy5) conjugated mouse anti-
human CD19 antibody were from Dako (Carpinteria, CA). Cy2-conjugated  donkey anti-
mouse IgG antibody was from Jackson ImmunoResearch (West Grove, PA) . Hepes and
LipoFectamineTM 2000 reagent, Taq DNA polymerase, Opti-MEM I medium, fetal calf
serum (FCS) and normal horse serum were from Life Technologies, Inc. ( Galthersburg,
MD).  Wizard Genomic DNA Purification Kit was bought from Promega (Madison, WI).
ABgene Total RNA Isolation Reagent was from Advanced Biotechnologies Ltd (Surrey,
U.K.).  QIAquick Gel Extraction Kit was from QIAGEN Pty Ltd (Clifton Hill, Vic,
Australia). QuikChangeTM  Site-Directed Mutagenesis Kit was purchased from Stratagene
(La Jolla, CA).
Antibody production and preparation. Two types of  mouse anti-human P2X7 receptor
monoclonal antibodies (mAbs, clone L4 and B2) were used in this study.  L4 was prepared
from hybridoma supernate by chromatography on Protein A Sepharose Fast Flow as
described previously (14).  Purified B2 was kindly provided by Dr Gary Buell. FITC
labeling kits were used to conjugate these two P2X7 antibodies according to the
manufacturers instructions. The conjugated L4 had 1.2 FITC per IgG and B2 had 1.1 FITC
per IgG.  Both anti-P2X7 antibodies showed no binding to the surface or cytoplasm of
HEK293 cells, a cell line which does not express this receptor in sub confluent
conditions(15). These two mAbs showed similar surface binding to human hemopoietic
cells at a saturating concentration of 60 µg/ml.  However, L4 strongly blocks P2X7
receptor function (12,14) while B2 inhibits < 7% of P2X7 receptor function (Buell G,
unpublished observation).
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Source of human leucocytes.  Peripheral blood lymphocytes and monocytes were obtained
from 45 normal subjects while the patient with B-chronic lymphocytic leukemia (CLL 4)
has been reported in our previous study (12).  Mononuclear cells were separated on Ficoll-
Hypaque and washed once and resuspended in Hepes-buffered NaCl medium (145 mM
NaCl, 5 mM KCl, 10 mM Hepes pH 7.5, 5 mM D-glucose, 1 g/L BSA).  In experiments on
monocyte-derived macrophages, a mononuclear preparation was incubated for 12 hours in
plastic flasks, gently washed to remove non-adherent cells and the adherent monocytes
cultured for 7 days in RPMI-1640 medium plus 10% human AB serum and 100 ng/ml
interferon-γ.  Macrophages were then detached by mechanical scraping for flow cytometric
analysis.
Cultured HEK-293 cells. Human embryonic kidney cells (HEK- 293) were cultured in
RPMI-1640 complete medium supplemented with 10% heat-inactivated fetal calf serum, 2
mM glutamine, and 0.02mg/ml gentamicin.
Ethidium influx measurement by flow cytometry. Cells (2x106) prelabeled with
appropriate fluorophore-conjugated anti-CD mAbs or anti-P2X7 mAb (clone B2) were
washed once and resuspended in 1.0 ml HEPES buffered KCl medium (10mM HEPES,
150 mM KCl, 5 mM D-glucose, 0.1% BSA, pH 7.5) at 370C. Cells were analysed at 1000
events per second on a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA)
and were gated by forward and side scatter and by cell type specific antibodies. All
samples were stirred and temperature controlled at 37oC using a Time Zero module (Cytek,
Fremont, CA).  Ethidium (25µM) was added, followed 40 seconds later by addition of 1.0
mM ATP.  The linear mean channel of fluorescence intensity for each gated subpopulation
over successive 5 seconds intervals was analysed by WinMDI software (Joseph Trotter,
version 2.7) and plotted against time.  To correct for any slight variation in the
performance of the flow cytometer, fluorescent standard beads (Flow Cytometry Standards
Corp, Research Triangle Park, NC) were analyzed each day(9).
Cytosolic Ba2+ measurements by fluorometry.  Lymphocytes  (1x107/mL) were washed
once and loaded with 2 µM Fura-2-acetoxymethyl ester by incubation at 37°C for 30 min
in Ca2+ free Hepes buffered NaCl medium.  Cells were washed once and incubated in
Page 7 of 23
Hepes buffered NaCl with 1 mM Ca2+ for another 30 min.   Lymphocytes were then
washed twice and resuspended in 3 mL Hepes buffered KCl medium at a concentration of
2x106/mL.  These samples were stirred at 37°C and stimulated with 1 mM ATP after
addition of 1.0 mM BaCl2.  Entry of Ba
2+ into cells loaded with fura-2 produces changes
almost identical to those produced by Ca2+ in the excitation and emission spectra of Fura-2.
Fluorescent signals were recorded on a Johnson Foundation Fluorometer with excitation at
340 nm and emission at 500 nm.    Calibration of Fmax and Fmin was performed after each
run by adding 25 µM digitonin followed by 50 mM EGTA.  Control experiments showed
that addition of ATP did not release Ca2+ from the internal stores of lymphocytes
suspended in medium containing EGTA.
DNA extraction and PCR. Genomic DNA was extracted from peripheral blood using the
Wizard Genomic DNA Purification System. A primer pair was designed within exon 13 of
the P2X7 gene to amplify a 356 bp product from genomic DNA.  P2X7 oligonucleotides
were synthesized by Life Technologies.  The forward primer was 5’-
ACTCCTAGATCCAGGGATAGCC-3’ and the reverse was 5’-
TCACTCTTCGGAAACTCTTTCC-3’.   PCR amplification (35 cycles of denaturation at
95oC for 45 sec, annealing at 52oC for 45 sec and extension at 72oC for 1 min) produced a
fragment of the expected 356 bp size.   PCR products were separated in 2% agarose gel
and visualised by ethidium bromide staining.
DNA sequencing for PCR products. Amplified PCR products were purified using
QIAquick Gel Extraction Kit protocol. Using AmpliTaq FS dye terminator cycle
sequencing kit (Perkin-Elmer Applied Biosystems, USA), fluorescence-based cycle
sequencing reaction was performed to sequence the PCR products of P2X7 directly from
both ends using specific primers. Sequencing electrophoresis was carried out on the ABI
PRISM 377 DNA Sequencer and the ABI PRISM Sequencing Analysis software (version
3.0) was used for the analysis.
Site-Directed Mutagenesis. The full-length clone of hP2X7 (GenBank accession number
Y09561) was used in these studies.  hP2X7 cDNA was kindly provided by Dr. Gary Buell
as a Not I-Not I  insert in pcDNA3 (Invitrogen).  hP2X7 was removed from pcDNA3 using
a Not I-Not I digest and ligated into pCI (Promega), which is a CMV (cytomegalovirus)
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driven mammalian expression vector.  Mutant A1513C (E496A) was introduced using
overlap PCR (Quick ChangeTM Site-Directed Mutagenesis Kit, Stratagene) using the
expression vector pCI-hP2X7 as a template.  The P2X7 point mutation was constructed
using a pair of complementary mutagenic primers, consisting of the mutagenic codon
flanked by sequences homologous to the wild-type strand of the template.  After digestion
of the parental DNA with Dpn I, intact mutation–containing synthesized DNA was
transformed into competent DH5α cells.  All mutations were confirmed by sequencing.
The primer sequences were as follows:
A1513C (Glu496Ala) forward: GG.TGC.CTG.GAG.GCG.CTG.TGC.TGC.CGG;
A1513C (Glu496Ala) reverse: CCG.GCA.GCA.CAG.CGC.CTC.CAG.GCA.CC.
Base changes introducing the mutations are in bold type and underlined.
P2X7 transfection into HEK293 cells. Full length P2X7 cDNA in a plasmid vector
pcDNA3 or the mutated P2X7 in pCI as above was  transfected into HEK-293 cells by the
Lipofectamine 2000 Reagent.  Transfection experiments always employed the minimum
amount of cDNA which gave surface P2X7 expression.  After 40 - 44 hours, cells were
collected by mechanical scraping in RPMI-1640 medium containing 10% FCS.
Immunofluorescent staining and confocal microscopy Plastic non-adherent mononuclear
cells were incubated on poly-L-lysine-coated (0.1 mg/ml) glass coverslips for 60 min.
Fixed cells (4% paraformaldehyde) were blocked with 20% horse serum/0.1% bovine
serum albumin before incubating with anti-human P2X7 receptor mAb or isotype control
antibody and subsequent labeling with Cy2-conjugated donkey anti-murine IgG antibody.
Cells were visualised with a Leica TCS NT UV laser confocal microscope system as
previously described (16).
ATP-induced cytotoxicity assay  Lymphocytes (1 x 107/ml) were incubated with 200 µM
BzATP for 15 min at 37oC in Hepes buffered NaCl medium, washed once and incubated in
RPMI-1640 medium with 10% FCS for 24 hours. Cells were washed once and stained
with FITC-anti-CD3 mAb and 7-AAD (20 µg/ml) for 20 min at room temperature.  Viable
and non-viable cells were measured by flow cytometry as previously described (17).
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RESULTS
P2X7 function in monocytes and lymphocytes
Our previous data has shown that P2X7 receptor function in monocyte or lymphocyte
subsets can be measured by the ATP-induced uptake of ethidium at 37oC using time-
resolved two-color flow cytometry (12).   Mononuclear preparations from 32 normal
subjects were pre-incubated with appropriate FITC-labeled monoclonal antibodies and
ATP-induced uptake of ethidium into gated monocyte and lymphocyte subpopulations was
measured. Ethidium uptake through the P2X7 channel/pore was 5-fold greater for
monocytes than for B- T- or NK-lymphocytes of normal origin but for all cell types there
was variation in the functional response of the P2X7 receptor (Fig.1) One subject showed
complete lack of P2X7 function in both monocytes and lymphocytes shown in Fig. 1 by the
filled circles.  Variability in ATP-induced dye uptake into monocytes has been observed by
others (13).
Identification of a single nucleotide polymorphism in the C-terminal tail of P2X7 gene
Since the long carboxyl-terminal tail of the P2X7 receptor regulates its permeability
properties, the sequence of genomic DNA corresponding to this region was analysed.
Thus a PCR product was amplified directly from DNA between nucleotide 1425 and 1780
of the coding region of the P2X7 gene and the product was sequenced.  In 9 of 45  subjects
a heterozygous nucleotide substitution (adenine  to cytosine) was found at position 1513
while in 1 out of 45 subjects a homozygous A1513C substitution was observed (Fig. 2).
Since the fractional frequency of the mutant allele was 11/90 (0.122) in the Caucasian
population it fulfils the criterion for a single nucleotide polymorphism.  The deduced
amino acid change for this mutation is glutamic acid to alanine at amino acid 496
(Glu496Ala) of the P2X7 protein.
The A1513C mutation is present in skin fibroblasts
Skin fibroblasts were cultured from a punch-biopsy of skin from the homozygous normal
subject, DNA was extracted and a product amplified using primers for the C-terminal tail
of the P2X7  gene.  Sequence analysis of the product showed only cytosine to be present at
position 1513 (results not shown).
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Surface expression of P2X7 is not affected by the polymorphism
Large amounts of P2X7 protein are found in an intracellular location in monocytes and
lymphocytes of all subtypes (12) and we studied whether the A1513C mutation may have
reduced the surface expression of this receptor.  Confocal microscopy showed strong
surface expression of the P2X7 receptor on lymphocytes from subjects who were germline
or homozygous for this mutation (Fig.3) while monocytes showed a similar strong surface
P2X7 expression (data not shown).  Flow cytometric measurement of P2X7 expression
using a monoclonal antibody to the extracellular domain of P2X7 (14) showed that the
surface expression of this receptor on either B- or T-lymphocytes from heterozygous or
homozygous patients was not significantly different from B- or T-lymphocytes which were
of  germline sequence at position 1513 (Table 1).
Correlation of P2X7 function with the polymorphism
The function of P2X7 receptors expressed on lymphocytes or monocytes was compared
with the genotype at position 1513 of the P2X7 gene.  Typical ethidium uptake curves for
monocytes, B- T- and NK-lymphocytes are shown in Fig. 4 for normal subjects each with
germline, heterozygous and homozygous DNA at position 1513. A single patient with B-
CLL from our previous study (12) and homozygous A1513C is included in Fig. 4 and
Table 1 for comparison. Homozygosity for the mutation led to almost complete loss of
function of the receptor while heterozygosity for the mutation gave a function
approximately half that of the germline P2X7 sequence (Fig. 4a, b, c, d). Measurement of
P2X7 function in a larger group of subjects (n = 20, Table 1) showed that the mean ATP-
induced ethidium uptake was reduced in heterozygous subjects to half the uptake found in
subjects with germline sequence, and this magnitude of reduction was found for the four
cell types studied; monocytes (p<0.001) B- (p<0.002) T- (p<0.005) and NK-lymphocytes
(p<0.03).  ATP-induced uptake of Ba2+ was also studied into lymphocytes prepared from
the subject with homozygous mutant P2X7.  These cells failed to respond to ATP (Fig. 5)
indicating that the mutant P2X7 channel was non-functional to small inorganic cations as
well as ethidium+ as permeants(12).
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Function of A1513C mutated P2X7 transfected into HEK293
cDNA for germline P2X7 or P2X7 carrying the A1513C mutation was transfected into
HEK293 cells to study whether this mutation abolishes function in transfection
experiments.  At 40 hours after transfection the surface expression of the P2X7 receptor
was quantitated by binding of FITC-conjugated mAb (clone B2) and the ATP-induced
uptake of ethidium was studied in the same cell population by two-color flow cytometry.
Preliminary experiments suggested that the function of the mutated P2X7 depended on the
density at which this receptor was expressed on the cell surface.  For this reason a gating
strategy was adopted in which cells expressing none, low or high density of P2X7 receptors
were analysed as three separate populations (Fig. 6a, b, c).  The cohort of cells with
negative P2X7 expression showed no ATP-induced ethidium uptake with either germline
or mutated cDNA (Fig. 6d). The cohort of cells with low expression of the P2X7 receptor
showed strong ATP-induced ethidium uptake in the germline P2X7 but the mutant P2X7
had no function (Fig. 6e).  However in the cohort of cells with the highest P2X7 surface
expression, substantial ATP-induced ethidium uptake was observed both for the germline
and to a lesser extent for the mutant P2X7 (Fig. 6f).  These data suggest that the impaired
function of the P2X7 receptor in cells carrying the Glu496Ala mutation could be reversed
when the density of the mutant receptor was increased on the cell surface.
Homozygous Mutant P2X7 regains partial function in macrophages
Differentiation of monocytes into macrophages greatly increases both the expression and
function of the P2X7 receptor (18,19). Peripheral blood monocytes were cultured with
interferon-γ for 7 days and the function of P2X7 receptor was measured in the CD14+
macrophage population.  Macrophages from subjects with germline P2X7 showed an ATP-
induced ethidium uptake about 5-fold greater than their precursor monocytes (Fig. 7a).
Thus the area under the ATP-induced ethidium uptake curve increased from 28,920 units
on day 0 to 160,000 units in day 6 macrophages. Macrophages from a subject homozygous
for A1513C polymorphism developed partial P2X7 function compared to the absent
function in the precursor monocytes (Fig. 7b; zero units on day 0 to 30,800 units on day 6).
Although the P2X7 expression (mean channels fluorescence intensity) on germline
monocyte/macrophages increased from 48 to 284 this increase was less in the homozygous
mutant cells (from 51 to 96).  Thus the functional defect associated with the Glu496Ala
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polymorphism in monocyte/macrophages could be partially reversed when the abundance
of native P2X7 was increased on the cell surface.
ATP-induced cytotoxicity  is impaired by the homozygous P2X7 polymorphism
P2X7  mediated cytotoxicity was studied in lymphocytes from subjects who were germline
or homozygous for the Glu496Ala polymorphism. A mononuclear preparation of
peripheral blood was exposed to BzATP for 15 min, washed and incubated a further 24 hr
prior to  assay by two-color flow cytometry using (a) 7-amino-actinomycin D (7-AAD) as
a viability dye and (b) FITC-conjugated CD3 mAb to gate on the predominant T-
lymphocyte subpopulation.  The fluorescent dot-plots (Fig 8) identify two distinct
populations of viable cells (lower region) and non-viable cells (upper region) after 24 hr
incubation.  The % of non-viable cells was markedly reduced in the homozygote P2X7
mutant compared with germline T-cells (Fig 8a,b).  In control lymphocytes not exposed to
BzATP, the percentage of non-viable cell was 3.2% for germline and 6.6% for homozygote
after 24 hr incubation.
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DISCUSSION
The data in this study shows that the function of the human P2X7 receptor is affected by a
single nucleotide mutation of adenine to cytosine at position 1513 of cDNA which changes
glutamic acid to alanine at amino acid position 496. Homozygosity (C/C) for this
polymorphic mutation led to almost complete loss of P2X7 function in leukocytes while
heterozygosity (A/C) gave a function which was half that of cells with the germline P2X7
sequence.  The negative effect of this mutation on P2X7 function was evident in all
leukocytes which express surface P2X7, namely monocytes, B-lymphocytes, T-
lymphocytes and NK-cells.  Polymorphonuclear leukocytes or platelets which have only
weak or no surface expression of P2X7 (12) were not tested.  The finding that skin
fibroblasts from a homozygous A1513C subject also carry only cytosine at position 1513
indicates the constitutional nature of this mutation which affects tissues other than
leukocytes. The fractional frequency of the mutant A1513C allele in the normal subjects
was 0.122 so that the mutant allele falls within the definition of a single nucleotide
polymorphism defined by a prevalence greater than 0.01 (1%) in the population.
Application of the Hardy-Weinberg equilibrium to the A1513C allele frequency found at
the DNA level yields an expected value of 0.7 homozygotes which is not significantly
different to the observed value of 1 (X2 = 0.21 with one degree of freedom).   Single
nucleotide polymorphisms are increasingly recognised as a source of genetic variation and
their density may be as high as one per kb of cDNA (20).  Most of these polymorphisms
have a neutral effect on function, but some contribute to loss of protein function such as
found with this A1513C allele.    In a recent study of B-CLL our group found 3 of 12
patients demonstrated low or absent function of the P2X7 receptor in the malignant B-
lymphocytes as well as in the normal monocytes of peripheral blood (12) .  One of these
three patients carried the A1513C mutant P2X7 allele in homozygous dosage; while the
other two patients were germline at this position (Gu, Zhang and Wiley, unpublished).
Clearly A1513C is only one of several genetic changes which can inhibit the function of
the P2X7 receptor. It has been previously reported that truncation of the long carboxyl-
terminal tail of the rat P2X7 receptor abolishes ATP-induced uptake of large fluorescent
dyes such as Yo-Pro2+ (8) and truncation of the carboxyl terminal tail of the human P2X7
receptor also abolishes ATP-induced channel/pore formation (Gu and Wiley, unpublished).
For this reason we sought a loss-of-function mutation in the carboxyl terminus of P2X7.
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Truncation of a receptor often leads to failure of its surface expression such as shown for
the 10 amino acid deletion in the chemokine receptor CCR5 gene (21) or the 49 amino acid
deletion from the carboxyl terminus of the sulfonylurea receptor which prevents trafficking
of this receptor and its associated ATP-sensitive K+ channel to the surface of the pancreatic
β-cell (22).  However the Glu496Ala polymorphism in P2X7 allows full expression of the
mutant receptor on the cell surface as shown in Fig. 3 and Table 1 for both B- and T-
lymphocytes.
The polymorphic A1513C mutation of P2X7 changes glutamic acid to alanine at amino
acid 496 (Glu496Ala) and the present data suggests that this glutamic acid residue at
position 496 is centrally involved in the interactions which lead to formation of the P2X7
channel/pore. The molecular mechanisms underlying the opening of the cation channel and
its transition to a fully dilated pore are not resolved.  The simplest model for pore dilation
is that it is an intrinsic property of the P2X7 receptor that involves a small scale structural
change, perhaps in the selectivity filter of the channel (23).  Alternative views suggest that
pore dilation involves a large scale structural change such as that induced by the dynamic
addition of subunits to the existing oligomeric structure (24) or by an interaction with a
protein partner, or the activation of a molecularly distinct pore protein (25) by ligated P2X7
receptor.  The inability of some oocyte expression systems to display BzATP activated
pore formation (26,27) also provides evidence for regulation of the pore dilation. The
finding that the homozygous mutant P2X7 receptor is non-functional for both a small
cation, permeant Ba2+ as well as the larger ethidium+ emphasizes the importance of this
glutamic acid at position 496 both for immediate channel opening as well as its dilatation
to a pore.  The simplest explanation of the present data is that the glutamic to alanine
substitution in the mutant P2X7 weakens the electrostatic interactions governing the
assembly of the P2X7 channel complex in the plasma membrane.
Transfection of A1513C mutant P2X7 into HEK293 demonstrated that the loss of channel
function in mutant P2X7 could be reversed at high levels of surface expression of the
mutant receptor.  Two-color flow cytometry (Fig. 6) was used to directly compare
ethidium influx through the P2X7 pore in transfected cells gated into three subpopulations,
those expressing none, those with low and those expressing high levels of this receptor.
This gating strategy employed a FITC-conjugated mAb (clone B2) that binds to an
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extracellular epitope of P2X7 but does not inhibit the function of the receptor.  Thus ATP-
induced ethidium uptake was measured on the red (570 nm) channel into two cell
populations defined by high and low (R3 and R2 respectively) fluorescence on the green
FITC (525 nm) channel.  Germline P2X7 showed function at both high and low receptor
numbers at the plasma membrane.  In contrast the mutant P2X7 was non-functional at low
numbers but regained partial function at higher density of expressed receptors.  This
important finding was confirmed for the native P2X7 receptor which is upregulated when
monocytes from peripheral blood are cultured with interferon-γ to produce macrophages
(Fig. 7).  The function of germline P2X7 was stimulated about 5-fold in macrophages
compared with their precursor monocytes, but the mutant P2X7 only regained partial
function in macrophages compared with its zero function in precursor monocytes.
Increased receptor abundance may explain the partial restoration of mutant P2X7 channel
function since raising the receptor numbers in the membrane of either HEK293 cells (Fig.
6) or human macrophages (Fig. 7) would tend to compensate for weakened self
associations and promote receptor assembly by a direct mass action effect. Whatever the
mechanism of P2X7 assembly in the membrane, the data in Table 1 shows that much of
the person-to-person variation in P2X7 function can be explained by the genetic
polymorphism at amino acid position 496 of the P2X7 receptor molecule.
Both gain-of-function as well as loss-of-function mutations can affect genes encoding ion
channel proteins(23).  Thus an  asparagine to lysine polymorphism in the third intracellular
loop of the human α2A-adrenergic receptor enhances coupling to Gi in the presence of
agonist(28). Three loss-of-function mutations have been identified in the human K1R6.2
gene which encodes the two-transmembrane protein subunit of the pancreatic β-cell ATP
sensitive K+ channel(22). Loss-of-function mutations occur in the nompC gene, a six-
transmembrane ion channel in Drosophila responsible for mechanosensory signalling(29).
However, few if any genetic polymorphisms have been previously described in which one
allele encodes a non-functional channel.
Extracellular ATP has an emerging role in the immune system since P2X7 activation leads
to apoptotic death of thymocytes (30,31), B-lymphocytes (4), macrophages (2) and
dendritic cells (32,33).  Thus incubation of mononuclear cells from peripheral blood with
ATP gave substantial apoptotic death of T-lymphocytes but cell death was greatly
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attenuated in T-lymphocytes from the subject with homozygous Glu496Ala P2X7 protein
(Fig. 8). There is good evidence that activation of macrophage P2X7 receptors by ATP can
produce killing of intracellular Mycobacteria tuberculosis by these cells (13,34).
Stimulation of phospholipase D appears to be involved in the killing mechanism (35) and
one of the consequences of P2X7 activation is stimulation of the activity of phosphatidyl
choline-specific phospholipase D (36-40).  Other downstream effects of the P2X7 receptor
activation may also occur such as the generation of reactive oxygen intermediates and the
stimulation of intracellular caspases which not only kill the organism but also lead to the
apoptotic death or cytolysis of the host cell.  It is possible that the polymorphism described
above may be one of the susceptibility factors predisposing individuals to Mycobacterial
infections.  Thus study of the P2X7 knockout mouse (41) and its resistance to certain
infectious requiring competent macrophages for control will be important in defining a role
for this receptor.  Regardless of the clinical associations of the polymorphism at amino
acid 496, this loss-of-function mutation affecting the carboxyl terminal tail of P2X7 may
help unravel the molecular events leading to channel/pore formation.
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 Figure Legend
Fig. 1 Variability of P2X7 receptor function in normal human peripheral blood
mononuclear cell subsets. Mononuclear preparations (2 x 106/mL) prelabeled with cell type
specific antibodies (CD14 for monocytes, CD19 for B-lymphocytes, CD3 for T
lymphocytes and CD16 for NK cells) were suspended in Hepes-buffered  KCl medium at
37oC.  Ethidium (25µM) was added followed 40 s later by 1.0 mM ATP. Mean channel of
cell-associated fluorescence intensity was measured for each gated population at 5 s
intervals.  P2X7 function is shown as arbitrary units of area under ATP-induced ethidium
uptake curve in first 5 min incubation.
Fig. 2 Sequence of genomic DNA at the carboxyl terminal tail of the P2X7 gene showing
(a) germline (b) A1513C homozygous mutant and (c) A1513C  heterozygote.  A 356 bp
products was amplified by using a primer pair within exon 13 of P2X7 gene (forward:  5’-
ACTCCTAGATCCAGGGATAGCC-3’; reverse: 5’-TCACTCTTCGGAAACTCTTTCC-
3’).  PCR products were purified and sequenced directly from both ends using the same
primers.
Fig. 3 Confocal images of  P2X7 receptor expression on the surface of lymphocytes.
Lymphocytes from normal subjects, either (a) germline or (b) A1513C homozygote, were
labeled with anti-P2X7 receptor mAb (clone L4) and subsequently with Cy2-conjugated
anti-mouse IgG antibody. Isotype control antibody was included as negative control and
showed no staining. Calibration bar is 2 µm.
Fig. 4 Typical ATP-induced ethidium uptake curve in mononuclear cell subsets from
normal subjects with germline, A1513C heterozygous and A1513C homozygous P2X7 as
indicated. A single patient with B-chronic lymphocytic leukemia who was A1513C
homozygous P2X7 is included for comparison.  2 x 10
6 cells pre-labeled with appropriate
FITC-conjugated surface marker antibody were incubated in 1 ml Hepes buffered KCl  at
37oC. Ethidium bromide (25 µM)was added followed 40 s later by 1 mM ATP.  Mean
channel of cell-associated fluorescence intensity was measured at 5 s intervals for (a)
monocytes (gated CD14+), (b) B-lymphocytes (gated CD19+), (c) T-lymphocytes (gated
CD3+) and (d) NK cells (gated CD16+) population.
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Fig. 5  Ba2+ influx on lymphocytes from subjects with germline, A1513C homozygous and
heterozygous mutant P2X7. Lymphocytes (6x10
6) loaded with 2 µM Fura-2-acetoxymethyl
ester were resuspended in 3 mL Hepes buffered KCl medium.  1.0 mM Ba2+ was added 40
s before stimulation with 1.0 mM ATP as indicated.
Fig. 6 Surface expression (a,b,c) and function (d,e,f) of HEK293 cells transfected
transiently with germline and A1513C site-directed mutant human P2X7 cDNA.  1 µg
DNA and 6 µl LipoFectamine 2000 reagent was incubated in 300 µl Opti-MEM I medium
for 20 min. The mixture was then added to a 25 cm2 flask containing 5 x 106 HEK293 cells
in 3 ml medium.  Cells were collected after 40~44 hrs, washed once and incubated with 10
µg/ml FITC-conjugated mouse anti-human P2X7 mAb (clone B2) for 15 min at room
temperature. Cells were then washed once and resuspended in 1 ml Hepes buffered KCl
medium. Ethidium bromide (25 µM)was added followed 40 s later by 1 mM ATP.   Mean
channel of cell-associated fluorescence intensity was measured at 5 s intervals for gated
sub-populations which expressed P2X7 receptors on their surface at (d) zero (e) low (f)
high levels.  Data were collected at a constant flow rate of 1,000 total events per second.
The gating windows R1, R2, R3 were exactly the same for germline and mutant cells.
Control experiment showed negative expression and function of P2X7 on native HEK293
cells. Control experiments excluded an inhibitory effect of B2 monoclonal antibody on
P2X7 function.  Dotted line is isotype control, solid line shows the histogram for FITC -
P2X7 mAb in Figs. a, b, c.
Fig. 7 ATP-induced ethidium uptake on fresh monocytes and  monocyte derived
macrophages from normal subjects with germline and A1513C homozygous P2X7.
Monocytes from mononuclear preparations were allowed to adhere to plastic culture flasks
overnight and were cultured for another 6 days in medium plus 100 ng/ml interferon-γ.
Cells were collected by gentle mechanical scraping and labeled with FITC-anti-CD14
mAb.  Linear mean channel fluorescence intensity was measured in each 5 s interval on the
gated CD14+ population after 25 µM ethidium and 1 mM ATP were added.
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Fig. 8 BzATP-induced cytotoxicity of T-lymphocytes from subjects with germline and
A1513C homozygous P2X7.  Lymphocytes (1x10
7/ml) were incubated with or without 200
µM BzATP in Hepes buffer NaCl medium at 37oC for 15 min, washed once and
resuspended in RPMI-1640 medium with 10% FCS.  After 24 hours incubation cells were
labeled with FITC-anti-CD3 mAb and the viability dye 7-AAD.  The percentage of live
cells is shown in the lower region and non-viable cells in the upper region of each dot plot.








